

Pharmaceutical Barium & Iodine for Radiographic Contrast Media Products: X-Ray, MRI, CT Scan Applications

From The Earth To The Bottle

Building a fully integrated radiographic contrast company to service a global market

VOYAGEUR PHARMACEUTICALS LTD is moving forward to manufacture iodine & barium radiographic contrast suspension products for the health care industry. Voyageur has product manufacturing relationships in Canada, USA and India, that will allow Voyageur to fast track its production and sales of barite and iodine into this highly lucrative market to begin cash flow prior to quarry construction. Voyageur will begin contrast sales by buying third party source ingredients to begin cash flow quickly. Long term plan is for Voyageur to manufacture all our products with our 100% owned manufacturing facilities using our own 100% owned mineral feed stock to maximize profitability.

HEALTH CANADA PRODUCT LICENSES APPROVED & ISSUED

RADIOGRAPHIC CONTRAST MEDIA AGENTS are substances used to enhance the visibility of internal structures in X-ray-based imaging techniques such as computed tomography, projectional radiography, and fluoroscopy. Real time x-ray steroid and stem cell injections are creating high demand for iodine contrast in the pain management field.

FRANCES CREEK NI-43-101 BARIUM RESOURCE

Frances Creek barium project has 700 m of strike, open in all directions. It has been drilled along 220 m of strike, 90 m of true vertical depth, resulting in 166, 210 tonnes of indicated resource grading 37.75% barium sulfate and 195,578 tonnes of inferred resource grading 35.4% barium sulfate.

HIGH PURITY BARIUM SULFATE

The purity of the BaSO₄ at the Frances Creek deposit is exceptionally high. SGS Minerals confirms 98.6% BaSO₄ and that it meets all USP specifications for the pharmaceutical market. This ranks the Frances Creek barite project as one of the higher grade barium sulfate projects to be discovered worldwide.

TURN KEY MANUFACTURING

Voyageur has signed a cost plus manufacturing agreement with Alberta Veterinarian Laboratories Ltd, based in Calgary, Alberta. Voyageur preparing to create revenue in 2021.

WHAT IS BARITE & IODINE?

BARITE (Barytes, Barium Sulfate) is the naturally occurring mineral form of barium sulfate. The main properties are its high specific gravity (4.5) and very low solubility. It is a non-toxic environmentally friendly mineral that is not chemically reactive. In its purest and highest grade form, it is highly strategic and critical mineral for the health care sector. **IODINE** is a chemical element with symbol I and atomic number 53. The heaviest of the stable halogens, it exists as a lustrous, purple-black non-metallic solid at standard conditions. Iodine contrast is a highly consumed product in the health care sector.

BARITE & IODINE CONTRAST IS IN DEMAND!

As the world's population ages, the demand for pharmaceutical barite & iodine continues to increase. Currently North America is 100% reliant on USP barium sulfate imports. There is limited supply of natural occurring pharmaceutical barium sulfate and the Chinese domestic market demand has caused a drastic reduction in exports to North America. The North American market is currently reliant on expensive synthetic man made barium sulfate.



CREATING A TEAM OF RADIOGRAPHIC INDUSTRY EXPERTS

VOYAGEUR is working with Dash Consulting, a group with over 30 years of experience with R&D, formulating, manufacturing, global sales, and global logistics of barium radiographic contrast.

MARKETING & SALES

VOYAGEUR will focus marketing efforts on a global level. Voyageur is currently working on expanding product licenses Internationally.

HIGH DEMAND HIGH REVENUE STREAM

Owning the source minerals of our active pharmaceutical Ingredients (API) minerals, may allow Voyageur to be highly competitive. Voyageur is removing the multiple layers within the current radiographic contrast media supply chain. Our **Earth To The Bottle** strategy may allow our company to become highly competitive in a growing international market.

TWO STAGED DEVELOPMENT

VOYAGEUR is moving forward with a two stage strategy to introduce Barium & Iodine products to the market. Voyageur is fully integrating the barium contrast project as **stage 1**. Controlling all costs throughout the supply chain. **Stage 2** will involve the full integration of our Iodine contrast project. Controlling all costs from production from the well head to the bottle.

CORPORATE INFORMATION

SENIOR MANAGEMENT

Brent Willis, Bsc.Eng, President & CEO

Bradley C. Willis, P.Eng., COO

Ron Love, CA, Chief Financial Officer

INDEPENDENT CONSULTING

SGS Minerals & SGS Life Sciences Division

Alberta Veterinarian Laboratories

Dash Consulting LLP

WellDunn Consulting Inc

BOARD OF DIRECTORS

Brent Willis, BSc.Eng, President & CEO

Dr. Merle E. Olson, D.V.M., M.Sc.,

Trent Abraham, Chairman of the Board

Randy Henkle, P. Geo,

Ron Sifton, ICD.D, CPA.CA. Chair Audit Committee

Bradley Willis, P.Eng, COO

SHARE STRUCTURE,

April 1st, 2021

Issued: 89,000,000 (Basic)

Fully Diluted: 121,000,000 (rounded)



FOR MORE INFORMATION



LAWYERS

Burstall LLP

First Canadian Centre

350 7th Avenue SW, Suite 3400,

Calgary, AB, T2P 3N9

BANKING

Canadian Imperial Bank of Commerce (CIBC)

70 Crowfoot Way Northwest

Calgary, AB T3G 4C8

AUDITORS

Crowe MacKay LLP

Suite 1700, 717 – 7th Ave SW

Calgary, Alberta T2P 0Z3



FOR MORE INFORMATION

Brent Willis
President & CEO
brent@vpharma.ca
403 923 5944

Ron Love
CFO
RonL@Vpharma.ca
403 818 6086